

WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit Ministry of Health, Nutrition & Indigenous Medicine 231, de Saram Place, Colombo 01000, Sri Lanka

Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk Web: http://www.epid.gov.lk

Vol. 43 No. 28

02nd - 08th July 2016

Introduction of fractional dose IPV

Inactivated Polio Vaccine (IPV)

The first polio vaccine developed was the Inactivated Polio Vaccine (IPV). It was developed by Jonas Salk and came into use in 1955. IPV contains inactivated (killed) polio strains of all three polio virus types. This is the vaccine of choice for immunosuppressed individuals.

After administration, IPV produces sufficient serum antibody levels which protect the recipient from acquiring the infection via blood stream. However, it produces less gastrointestinal immunity than Oral Polio Vaccine (OPV). Because of that, persons who are immunized with IPV have a risk of getting infected with ingested wild polio virus. However, due to the immunity posed by IPV, it will prevent developing viraemia thus protecting the motor neurons. But, as IPV produces low gastrointestinal immunity, it does not reduce intestinal excretion of polio virus. For this reason, even though children immunized with IPV are less likely to develop poliomyelitis, they can still spread the wild polio virus to others.



Dosage of IPV is 0.5 ml, which can be given either subcutaneously or intramuscularly. Intramuscular route is preferred when it is given with other vaccines such as Diphtheria– Tetanus– Pertussis (DPT) or Hepatitis B. A minimum of four weeks interval should be there between two consecutive doses.

Contraindications to IPV are moderate to severe illness and severe allergy to vaccine components. IPV is a relatively safe vaccine where adverse effects are rare and uncommon. IPV should be stored at 2 ⁰ C to 8 ⁰ C. Freezing can affect the potency of the vaccine.

Disadvantages of IPV over OPV are producing less gastrointestinal immunity, being more expensive and being difficult to administer with the requirement of well trained staff. However, IPV has the main advantage of no risk of producing Vaccine Associated Paralytic Polio (VAPP).

Introduction of IPV

The global polio eradication is planned to be achieved in 2018 in Polio Eradication Endgame Strategies. In that, Polio type 2 withdrawal has been identified as an important step. Inactivated Polio Vaccine (IPV) introduction has been done in 2015 as an initial step in polio type 2 withdrawal procedure. This measure has been taken to ensure maintenance of polio type 2 immunity before the plan of switching over from trivalent OPV (tOPV) which contains live attenuated poliovirus types 1, 2 & 3 to bivalent OPV (bOPV) which contains only types 1 & 3.

Contents	Page
1. Leading Article – Introduction of fractional dose IPV	1
2. Summary of selected notifiable diseases reported $-(25^{th}-01^{st})$ July 2016)	3
3. Surveillance of vaccine preventable diseases & AFP -(25 th – 01 st July 2016)	4

WER Sri Lanka - Vol. 43 No. 28

Introduction of fractional dose IPV

Fractional dose IPV is administration of 0.1 ml of IPV which is a smaller dose, through intradermal route as two doses. This has the same efficacy of full dose IPV where 0.5 ml of IPV is administered Intramuscularly as a single dose.

Even though full dose IPV was introduced into the Expanded Programme on Immunization, there is a global scarcity of IPV production where polio low risk countries like Sri Lanka will receive the next stocks of IPV only in late 2017.

Therefore, the Advisory Committee on Communicable diseases (ACCD) has decided to change the full dose IPV schedule to a fractional dose IPV schedule.

This will be effective for Sri Lanka from 15th July 2016. For the smooth conduct of the process, Regional Epidemiologists are advised to arrange district level refresher training for Public Health Midwives on intradermal administration of the vaccine.

How to administer fractional dose IPV

Available IPV 5– dose vials will be used and only the administering schedule will be changed.

Doses, route and site of administration will be as follows,

- Fractional IPV should be given as two doses at the age of 2 months and 4 months, together with other 2 recommended vaccines of Oral Polio Vaccine and Penta valent vaccine at 2 and 4 months.
- Fractional dose IPV should be administered to the left arm (below the BCG scar)
- Sequence of vaccination of infants at 2 and 4 months of age at the visit of vaccination should be as follows,
 - Step 1– Give OPV first
 - Step 2– Give Pentavalent vaccine to left thigh
 - Step 3– Give fractional IPV to left arm
- IPV vaccine contraindications, side effects, vaccine safety and vaccine storage, injection safety and accountability will continue as the same
- IPV vaccine will continue to be used in open vial policy, taking all measures to minimize wastage.

Records and returns

Records and returns will continue as the same for existing IPV. However, following specific changes are essential to be effected in the documents



Child Health Development Record (CHDR)

Year, month and the date of the fractional IPV immunization along with the batch number of the fractional IPV vaccine doses should be recorded in the 2 rows mentioned under 'other' vaccines for 2 month and 4 month (until updated CHDR will be available) and it should be entered as 'fIPV 1' for the 2 month dose and 'fIPV 2" for the 4 month dose. It is mandatory to fill both A and B portions.

Other records

IPV column should be divided into 2 columns and should be mentioned as fIPV 1 and fIPV 2 in,

- The Clinic Immunization Register H 1216
- The Clinic summary RH– MIS518
- The Birth and Immunization Register EPI/03/79 (Revised 2014)

Infa	Infant Immunization														
BCG	Penta 1	Penta 2	Penta 3	DT 1	DT 2	DT 3	Polio 1	Polio 2	Polio 3	fIPV 1 IPV	fIPV 2	LJEV			

Quarterly EPI return– WEBIIS data entering will be changed for fIPV 1 and fIPV 2 and it is requested to enter relevant data separately in the relevant cages.

Sources

1. Immunization Handbook, Epidemiology Unit, Sri Lanka

2. Circular on Change of the Polio vaccination schedule: injectable Inactivated Polio Vaccine (IPV): Introduction of fractional IPV (fIPV)

Compiled by Dr. S.A.I.K. Sudasinghe of the Epidemiology Unit

Page 2

Table ²	Table 1: Selected notifiable diseases reported by Medical Officers of Health25th - 01st July 2016 (27th Week)																												
CD	C**	63	20	50	100	85	100	95	100	100	100	100	100	100	100	100	71	92	93	62	79	100	88	100	89	100	85	86	
WR	*⊢	56	7	7	87	54	100	60	75	94	100	50	80	100	80	64	14	83	59	46	47	57	76	82	50	73	54	63	
ini.	В	0	33	0	7	15	0	с	190	131	-	0	0	4	4	. 	പ	с	53	2	126	79	2	28	-	0	0	558	
-eishma Isis	A	0	0	0		0	0	0	. 25	٣	0	0	0	0	0	0	0	0	0	0	2	0	0	4	0	0	0	38	
itis	в	28	20	35	29	47	26	26	7	13	32	7	-	7	6	പ	-	6	35	25	24	11	113	17	90	31	13	662	
Mening	A	-	0	0	-	0	0	0	0	0	-	0	0	0	0	0	0	-	0	0	2	0	4	0	4	0	0	4	ess
×	В	225	83	131	08	22	83	178	146	110	108	6	7	23	10	63	78	113	187	45	145	73	17	43	112	194	55	568	npleten
ickenpc	7		-		-			-	~		+		0		0	0	0	~	-		~		+		-	~		2	C**-Cor
c	4	7	0			-	0	0			7		0		0	0	0	-		0	0		7 (2	0	щ С	4	0	eek: 296 (
Human Rabies	A	0	0	0	0	` 0	0	0	0	0	0	0	0	0	0	0	0	` 0	0	0	0	0	0	0	0	0	ء 0	0	current we
al H	В	18	16	13	39	13	26	9	21	17	ω	0	0	6	-	6	7	32	18	0	12	2	82	102	84	16	ю	551	d for the (
Vira	A	0	0	0	0	0	0	0	7	0	0	0	0	0	-	0	0	0		0	0	0	0	0	0	0	0	4	a provide
ohus ever	в	2	7	4	59	14	47	56	38	28	539	18	37	œ	£	4	0	20	20	58	22	-	55	78	21	18	0	1162	ng units dat
Typ Fe	۷	-	0	0	-	0	ę	2	0	-	9	0	0	0	0	0	0	2	2	-	-	0	-	0	-	0	0	22	of reporti
oirosis	В	116	127	251	82	56	29	174	80	116	8	11	ω	12	22	32	23	22	105	33	207	75	85	143	336	128	11	292	Number
Leptosp	A	0	0	2	ε	0	. 	e		2	0	0	0	0	0	0	0	0	9	0	4	-	-	с	6	2	0	38	units 339
ing	В	24	5	16	28	2	15	e	50	35	42	4	വ	28	36	88	20	24	11	0	22	10	22	10	22	45	40	507	f reporting
Food Poison	A	2	0	0	0	0	0	0	0	0	-	0	. 	0	0	0	0	0	2	0	0	0	0	0	0	-	0	10	number of
-ever	В	37	12	16	11	11	33	e	2	5	51	25	17	48	16	23	0	10	-	4	4	6	5	2	21	19	4	389	2016 Total
Enteric I	A	e	0	0	0	-	ę	. 	0	0	-	0		7	0	ę	0	0	0	0	0	0	0	0	-	-	0	22	01st July,
laliti I	В	3	5	3	13	-	. 	ω		11	3	0	4	e	2	0	. 	-	ω	2	-	2	10	-	20	15	3	22	or before : year.
Encept s	A	0	0	0	0	0	0	0	0	-	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	2	CD). eived on es for the
tery	В	83	34	39	106	33	56	60	34	75	133	26	13	ω	19	172	23	38	162	33	43	17	72	38	220	53	43	633	ses (WRC eturns rec Ilative cas
Dyseni	A	-	0	0	· m		4	с	m	11	4	0	2	, -	2	10	0	-	9	2	6	0	0	-	с С	5	0	69 1	 Diseas efers to r B = Cumu
ever	В	369	191	363	553	02	92	93	22	43	337	52	96	63	20	24	16	94	236	53	25	26	90	86	405	82	66	799	nunicable neliness r nt week.
ngue Fe		1 73	2(-1	2 15	e	-	8	4	2			<u> </u>	-	-	m	-	2	1,	6	°	2	3	-	17	7	3	6 22	s of Comr •T=Tir the currer
Der	A	351	34	2	172	49	21	22	32	59	33	-	-	7	2	7	0	9	76	22	13	10	29	5	66	28	2	105	Returns 3d during
RDHS Division		Colombo	Gampaha	Kalutara	Kandy	Matale	NuwaraEliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmune	SRILANKA	Source: Weekly A = Cases reporte
																												Pa	age 3

WER Sri Lanka - Vol. 43 No. 28

Table 2: Vaccine-Preventable Diseases & AFP

25th - 01st July 2016 (27th Week)

02nd- 08th July 2016

Disease				No. of Ca	ses by l	Province	ę		Number of cases during current	Number of cases during same	Total number of cases to	Total num- ber of cases to date in	Difference between the number of	
	W	С	S	N	E	NW	NC	U	Sab	week in 2016	week in 2015	2016	2015	in 2016 & 2015
AFP*	00	00	00	01	00	00	00	00	00	01	01	33	39	-15.3%
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0%
Mumps	00	01	01	01	01	02	01	00	00	07	04	222	209	+6.2%
Measles	00	00	01	00	00	01	00	00	00	02	40	288	1334	-78.4%
Rubella	00	00	00	00	00	00	00	00	00	00	00	06	06	0%
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	00	0%
Tetanus	00	00	00	00	00	00	00	00	00	00	00	04	10	-60%
Neonatal Teta- nus	00	00	00	00	00	00	00	00	00	00	00	00	00	0%
Japanese En- cephalitis	01	00	00	00	00	00	01	00	00	02	00	07	07	0%
Whooping Cough	00	00	00	00	00	00	01	00	00	01	00	31	44	-29.5%
Tuberculosis	94	27	17	02	17	03	06	06	26	198	346	4932	5057	-2.4%

Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam, AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS, Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis

CRS** =Congenital Rubella Syndrome

AFP and all clinically confirmed Vaccine Preventable Diseases except Tuberculosis and Mumps should be investigated by the MOH



Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. **Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication**

ON STATE SERVICE

Dr. P. PALIHAWADANA CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10